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OBJECTIVES: GBS is a neuromuscular disease affecting
180 to 720 Canadians each year. Patients with GBS may
be paralyzed for months, and up to 15% of affected
patients are left with a long-term disability. Until rela-
tively recently, standard therapy for GBS was a 5-day
course of PE. As an alternative to PE, more recent 
randomized trials demonstrate that intravenous IVIG is
equally effective to PE, but has fewer side effects and is
easier to administer. Since clinicians have two options for
the treatment of GBS, a cost utility analysis was con-
ducted to determine which of these two treatments is the
most cost effective. METHODS: A decision model was
developed to simulate treatment response and disease
recurrence over a 12-month time horizon. Clinical data
were obtained from a meta analysis of randomized trials.
Six experienced nurses were interviewed to obtain Health
care resource utilization data. Utility values were
obtained through interviews with 12 GBS health care
providers using the Time Trade-Off technique. RESULTS:
Based on the resource use data collected, the mean direct
cost of a 5-day treatment of IVIG and PE was $9785
(95% CI: $9637–$9933) and $7508 ($6577–$8439)
respectively. Using cost and utility estimates from IVIG
and PE, the cost per quality adjusted life year (QALY)
gained with IVIG was $35,700. In addition all of the
health care providers interviewed preferred the use of
IVIG instead of PE for their patients. CONCLUSIONS:
For the treatment of GBS, IVIG has a more favorable side
effect proﬁle and is easier to administer than PE. These
product attributes result in an incremental cost per QALY
gained that is considered economically acceptable by
current standards.
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OBJECTIVES: To examine utilization of various narcotic
analgesics that are used in pain management of occupa-
tional injuries among West Virginia Worker’s Compensa-
tion claimants. METHODS: We reviewed all claimants
(N = 20,282) who had any narcotic analgesic prescrip-
tion reimbursement during a period between July 1, 1997
and June 30, 2002. This accounted for 8% of all injury
claimants (N = 253,841) and 53.5% of all claimants 
with any prescription reimbursements (N = 37,903). We
analyzed all narcotic analgesic claims by types of drug,
extent, and duration of use and cost of the drug. We 
also studied the trend and pattern of utilization of these
medications between ﬁscal years FY1998 and FY2002.
RESULTS: The proportion of claimants with narcotic
analgesic prescription reimbursements increased by
almost 3 times from 7.8% in FY1998 to 24.4% in
FY2002. During the same period, total costs of narcotic
analgesics increased by 18 times. Most of the narcotic
analgesics were utilized in claimants who had a diagno-
sis of multiple musculoskeletal sprains (40.8%), multiple
injuries (21.2%), severe trauma (20.6%) and back injury
(7.0%). Twenty-nine percent of cases utilized more than
one narcotic analgesic. The most frequently prescribed
narcotic analgesic was hydrocodone with acetaminophen
(40.8%), followed by propoxyphene napsylate (12.6%),
Ultram (11.8%) and Oxycontin (8.9%). Although Oxy-
contin was utilized in 8.9% of the claimants, it accounted
for 34.8% of the total narcotic analgesic expenditure in
this population. Of all the narcotic analgesics, Oxycon-
tin had the highest median cost ($453 per claimant) and
median duration of use per claimant (97 days). CON-
CLUSION: Cost and utilization of narcotic analgesics
have dramatically increased over the past ﬁve years
among WV Workers Compensation claimants. Almost
90% of narcotic analgesic utilization is concentrated in
claimants with diagnosis of musculoskeletal sprains,
severe trauma, back and multiple injuries. High utiliza-
tion and duration of use of Oxycontin needs attention due
to its highly addictive nature and cost implications.
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OBJECTIVES: The objectives of this study were to deter-
mine and compare the prevalence and direct costs of back
pain in the U.S. in 1996 and 1999. METHODS: Retro-
spective analysis was conducted of the 1996 and 1999
portions of the Medical Expenditure Panel Survey
(MEPS). The MEPS collected data from nationally repre-
sentative samples of 22,601 respondents (1996) and
24,618 respondents (1999) and from respondents’ health
care and insurance providers. Data used for this study
included medical conditions and use and payments for
medical care. Back pain patients were identiﬁed using
ICD-9-CM codes determined by an expert panel of physi-
cians and professional coders as indicative of back pain.
Direct costs were calculated using patient and third-party
payments for back pain related medical events by type of
medical care. Sample estimates were weighted and pro-
jected to the population and 95% conﬁdence limits were
calculated using the Taylor expansion method. RESULTS:
There was no signiﬁcant difference in the prevalence of
back pain between 1996 (8.74%) and 1999 (9.00%).
From 1996 to 1999, total direct costs increased from
$14,701,417,650 to $25,847,917,882. Total inpatient
stay expenditures represented the largest proportion 
of this increase in direct costs, increasing from
$4,658,655,867 (mean = $10,016; 95% CL =
$9,463–$10,579) to $12,809,062,318 (mean = $17,305;
95% CL = $4,762–$29,847). Total expenditures on home
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health care services increased from $725,019,395 (mean
= $395; 95% CL = $140–$650) to $3,049,290,075 (mean
= $1,802; 95% CL = $618–$2,987). Total prescription
medication expenditures increased from $941,406,990
(mean = $24; 95% CL = $18–$29) to $1,202,568,785
(mean = $34; 95% CL = $30–$37). Expenditures on
ofﬁce-based medical provider and emergency department
visits showed minor increases while those on outpatient
services exhibited a minor decrease. CONCLUSIONS:
From 1996 to 1999, there was no difference in the preva-
lence of back pain however there was an $11.1 billion
increase in direct costs. Inpatient stays, home care ser-
vices, and prescription medications accounted for the
majority of this increase.
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OBJECTIVES: Gabapentin and topical lidocaine patch
(LIDO) are US FDA approved drugs for treatment of 
postherpetic neuralgia (PHN); tricyclics and opioids are
also frequently used. The cost-effectiveness of drug
therapy (Rx) for PHN is unclear. METHODS: We devel-
oped a Markov decision model to estimate the incremen-
tal cost-effectiveness of 5 management strategies for
established PHN in 70 year olds: no therapy, gabapentin,
LIDO, tricyclic (nortriptyline), or opiod (long acting mor-
phine). The analysis took a societal perspective, using 
reference case recommendations of the Panel on Cost-
Effectiveness in Health and Medicine. We used literature
data for parameter values, assuming that Rx related pain
relief equaled decreased PHN disutility. We also assumed
that gabapentin, nortriptyline, and opiod had identical
side effect likelihood (30%) and severity (possible bias
against gabapentin). One-way and multiway sensitivity
analyses were performed. RESULTS: In the baseline
analysis, nortriptyline is eliminated by extended domi-
nance. Compared to no treatment, opioid costs $60,000
per quality adjusted life year (QALY) gained. Compared
to opioid, gabapentin costs $74,000/QALY. Compared to
gabapentin, LIDO costs $795,000/QALY. In sensitivity
analyses, LIDO is preferred (<$75K/QALY) if pain relief
was >31% (baseline 23.8%) or if only 1 patch is required
(baseline 2). Opiod is not preferred if disutility due to
stigma is associated with its use but is preferred if pain
relief is >33% (base 32.3%). Nortriptyline is preferred if
pain relief is >22.5% (base 19.0%). Gabapentin domi-
nates all other Rx if its side effect frequency is <28%.
Monte Carlo analysis, with variation of all sensitive para-
meters over clinically plausible ranges, conﬁrms greater
economic acceptability of gabapentin. CONCLUSIONS:
In an analysis biased against its use, gabapentin is the
most economically reasonable choice for drug therapy of
established postherpetic neuralgia.
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OBJECTIVE: There is a lack of updated information on
healthcare expenditures and expenditure patterns for
individuals with back pain in the US. The objective of this
study is to use a recently released national survey data-
base to estimate total healthcare expenditures incurred 
by individuals with back pain in the US, calculate the
incremental expenditures attributable to back pain
among these individuals, and describe healthcare expen-
diture patterns of individuals with back pain.
METHODS: This study used data from 1998 Medical
Expenditure Panel Survey (MEPS), a national survey on
healthcare utilization and expenditures. Total healthcare
expenditures and per-capita expenditures among individ-
uals with back pain were calculated. Multivariate regres-
sion models were used to estimate the incremental
expenditures attributable to back pain. The expenditure
patterns were examined by stratifying individuals with
back pain by socio-demographic characteristics and
medical diagnosis, and calculating per-capita expendi-
tures for each stratiﬁed category. RESULTS: In 1998,
total healthcare expenditures incurred by individuals with
back pain in the US reached $90.7 billion and total incre-
mental expenditures attributable to back pain among
these persons were approximately $26.3 billion. On
average, individuals with back pain incurred expenditures
about 60% higher than individuals without back pain
($3495 vs. 2178). Among back pain individuals, at least
75% of service expenditures were attributed to those with
top 25% expenditure and per-capita expenditures were
generally higher for those who were older, female, whites,
medically insured or suffered from disc disorders. CON-
CLUSIONS: Healthcare expenditures for back pain in the
US in 1998 were substantial. The expenditures demon-
strated wide variations among individuals with different
clinical, demographic and socioeconomic characteristics.
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OBJECTIVE: To compare the drug utilization patterns,
in particular the compliance and persistency of therapy,
